Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a BRCA mutation would benefit.
Use these link to learn more:
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/167483/download